Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of galantamine for the treatment of Alzheimer's disease
ChiCTR2400094516Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of galantamine in Alzheimer's disease (AD) and confusion (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoints: Activity of Daily Living Scale (ADL), Mini Mental State Examination (MMSE) and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)confusion
Beyond the preview
Go deeper on ChiCTR2400094516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094516.